☀️ Graves' Disease TSH Receptor Antibody Mechanism Simulator

The Hypothalamic-Pituitary-Thyroid Feedback Axis

Healthy thyroid output is a tightly closed feedback loop, not a one-way switch.

• 0.4–4.0 mIU/L: Normal TSH range (typical serum reference range)
• Follicular cell membrane: TSH receptor location (G-protein coupled receptor)
• Negative: Feedback loop (high T3/T4 suppresses TSH)
• Regulated: Hormone production (matched to metabolic demand)

TSH binds and activates the receptor

Pituitary TSH binds thyroid receptors, triggering cAMP signaling and hormone synthesis.

Rising hormone shuts off further release

High circulating T3/T4 signals the pituitary to reduce further TSH secretion.

This closed loop keeps hormone output matched to the body's actual needs.

B Cells Produce TRAb / TSI Autoantibodies

Immune tolerance breaks down and autoreactive B cells target the thyroid receptor.

• TSI: TRAb subtype (thyroid-stimulating immunoglobulin)
• TSH receptor: Autoantibody target (on follicular cell surface)
• Autoreactive clones: B cell origin (escape immune tolerance checkpoints)
• ~1% of adults: Graves prevalence (more common in women)

Loss of tolerance to self-antigen

Autoreactive B cells recognize the TSH receptor as a foreign target.

Plasma cells secrete TRAb into circulation

Antibody levels climb gradually, still low relative to normal TSH signaling.

Early autoimmunity can precede noticeable hormone changes by months.

TRAb Antibodies Bind and Activate the Receptor

TRAb mimics TSH's shape closely enough to trigger the same activating signal.

• >1.75 IU/L: TRAb detection (typical Graves diagnostic threshold)
• TSH-like agonism: Receptor mimicry (antibody activates same receptor)
• cAMP cascade: Signal pathway (drives hormone synthesis genes)
• Prolonged: Binding duration (unlike transient TSH binding)

Antibody-receptor binding mimics natural ligand

TRAb occupies the TSH binding site and activates downstream signaling.

Hormone output begins rising above baseline

Sustained receptor activation pushes T3/T4 synthesis progressively higher.

Both TSH and TRAb converge on the same activating receptor pathway.

The Critical Difference — No Negative Feedback

Unlike pituitary TSH, antibody secretion is not suppressed by high hormone levels.

• Bypassed: Feedback status (antibodies unaffected by hormone level)
• Suppressed: Pituitary TSH (normal feedback still works there)
• Continues: Antibody production (independent of hormone levels)
• Autonomous drive: Net effect (receptor stays constantly activated)

Pituitary TSH correctly shuts down

High T3/T4 successfully suppresses pituitary TSH release, as expected.

B cells keep producing TRAb regardless

Antibody secretion has no hormone-sensing checkpoint to slow it down.

The receptor no longer "listens" to the body's own regulatory signal.

Continuous, Unregulated Hormone Overproduction

Receptor stimulation persists despite already-elevated hormone, producing Graves' hyperthyroidism.

• Elevated: Free T4 (often 2–4x upper normal)
• Hyperthyroidism: Clinical outcome (tachycardia, weight loss, tremor)
• Diffuse enlargement: Gland response (goiter from chronic stimulation)
• TRAb / receptor axis: Treatment target (antithyroid drugs, radioiodine, surgery)

Hormone output climbs without a ceiling

T3/T4 keeps rising because nothing throttles ongoing antibody-driven stimulation.

Autonomous drive defines Graves' disease

Treatment must target the antibody or receptor, not the feedback loop.

Lowering TRAb activity is the only way to restore normal control.